Overview of safety of non-biologic and biologic DMARDs.

@article{Ruderman2012OverviewOS,
  title={Overview of safety of non-biologic and biologic DMARDs.},
  author={Eric M. Ruderman},
  journal={Rheumatology},
  year={2012},
  volume={51 Suppl 6},
  pages={vi37-43}
}
Safety data come from a number of sources. Randomized clinical trials tend to be relatively short, exclude patients with significant comorbidity, have limited numbers of subjects and are primarily powered for efficacy. The most useful post-marketing data come from large national registries, such as Britain's BSRBR, Sweden's ARTIS, Germany's RABBIT, France's DANBIO, Spain's BIODASER and North America's CORRONA. Among the most commonly used non-biologic DMARDs, MTX is associated with risks of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…